Spoken Alpha
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals develops oral small-molecule therapies targeting estrogen receptor-positive breast cancer. The company's lead candidate, palazestrant, is in late-stage clinical trials as both a monotherapy and in combination with other targeted drugs for metastatic breast cancer.
Olema Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $900.4M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add OLMA, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OLMA.
$ curl https://api.spokenalpha.com/v1/companies/OLMAFAQ
Spoken Alpha indexes OLMA's earnings call transcripts at https://spokenalpha.com/companies/OLMA. Each call links to attributed speakers and parsed analyst Q&A. Olema Pharmaceuticals, Inc.'s own investor relations page is at https://ir.olema.com/news-and-events/news-releases.
Olema Pharmaceuticals, Inc. (OLMA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-0.60 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-0.61 | $-0.53 | -15.1% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.52 | $-0.54 | +3.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-01 | $-0.50 | $-0.52 | +3.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.49 | $-0.45 | -8.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.51 | $-0.44 | -15.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.36 | $-0.46 | +21.7% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $-0.51 | $0.17 | -100.0% | $364.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.60 | $-0.57 | -5.3% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.54 | $-0.54 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.56 | $-0.55 | -1.8% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-10 | $-0.49 | $-0.48 | -2.1% | $1.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.48 | $-0.51 | +5.9% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.49 | $-0.71 | +31.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.70 | $-0.69 | -1.5% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-0.65 | $-0.65 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.57 | $-0.78 | +26.9% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.82 | $-0.66 | -24.2% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.58 | $-0.60 | +3.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.54 | $-0.49 | -10.2% | $0 | — | — | EODHD |
Source: EODHD. OLMA reported actuals as published; sparse fields render as —.